Study approach | Population; studies; sample size | Follow-up (y) | Assumed population riske | Absolute effects | Certaintyf | What happens? |
---|---|---|---|---|---|---|
Hip fractures | ||||||
All eligible / offer-to-screen | Females 45–54 y [90] | The evidence from 1 RCT (n=2979) is very uncertain. | VERY LOWa-d | Very uncertain | ||
Females 68–80 y 1 RCT; 34,229 [5] | 5 | Study data: 25 per 1000 | 0.3 fewer in 1000 (4.2 fewer to 3.9 more) | LOWa-c | May not reduce | |
General: 20 per 1000 | 0.2 fewer in 1000 (2.4 fewer to 2.2 more) | |||||
Acceptors of screening | Females 45–54 y [90] | The evidence from 1 RCT (n=2604) is very uncertain. | VERY LOWa-d | Very uncertain | ||
Offer-to-screen in selected populationg | Females ≥65 y | 3 to 5 | Study data: 31 per 1000 | 6.2 fewer in 1000 (9.0 fewer to 2.8 fewer) | MODERATEc | Probably reduces |
General: 20 per 1000 | 4.0 fewer in 1000 (5.8 fewer to 1.8 fewer) | |||||
Males ≥70 y [68] | The evidence from 1 CCT (n=1380) is very uncertain. | VERY LOWa-d | Very uncertain | |||
Clinical fragility fractures | ||||||
All eligible / offer-to-screen | Females 45–54 y [90] | The evidence from 1 RCT (n=2979) is very uncertain. | VERY LOWa-d | Very uncertain | ||
Females 68–80 y 1 RCT; 34,229 [5] | 5 | Study data: 100 per 1000 | 1.0 fewer in 1000 (8.0 fewer to 6.0 more) | LOWa-c | May not reduce | |
General: 168 per 1000 | 1.7 fewer in 1000 (13.4 fewer to 10.1 more) | |||||
Acceptors of screening | Females 45–54 y [90] | The evidence from 1 RCT (n=2604) is very uncertain. | VERY LOWa-d | Very uncertain | ||
Offer-to-screen in selected populationg | Females ≥65 y | 3 to 5 | Study data: 84 per 1000 | 5.9 fewer in 1000 (10.9 fewer to 0.8 fewer) | MODERATEc | Probably reduces |
General: 168 per 1000 | 11.8 fewer in 1000 (21.8 fewer to 1.7 fewer) | |||||
All-cause mortality | ||||||
All eligible / offer-to-screen | Females 45–54 y 1 RCT; 4800 [90] | 9 | Study data: The evidence is very uncertain. | VERY LOWb,d | Very uncertain | |
General: 3 per 1000 | No difference in 1000 (0.8 fewer to 1.1 more) | LOWb,d | May not reduce | |||
Females 68–80 y 1 RCT; 34,229 [5] | 5 | Study data: 118 per 1000 | 3.5 fewer per 1000 (9.4 fewer to 3.5 more) | LOWb,d | May not reduce | |
General: 57 per 1000 | 1.7 fewer per 1000 (4.6 fewer to 1.7 more) | |||||
Offer-to-screen in selected populationg | Females ≥65 yh | 3 to 5 | Study data: 89 per 1000 | No difference in 1000 (7.1 fewer to 5.3 more) | MODERATEd | Probably does not reduce |
General: 57 per 1000 | No difference in 1000 (4.6 fewer to 5.1 more) | |||||
Serious adverse events | ||||||
Offer-to-screen in selected populationg | Females 70–85 y [6] | The evidence from 1 RCT (n=12,483) is very uncertain. | VERY LOWa,b,d | Very uncertain | ||
Health-related quality of life/Wellbeing | ||||||
All eligible / offer-to-screen | 9 (self-rated health) 2 (SF-36) | NA | The evidence from 1 RCT (n=2979) is very uncertain. | VERY LOWa-c | Very uncertain | |
Offer-to-screen in selected populationg | Females 70–85 y 1 RCT; 10,661 [6] | 5 | NA | SF-12 (range 0–100): Mental health: MD −0.30, 95% CI −0.86 to 0.26 Physical health: MD 0.30, 95% CI −0.21 to 0.81 EuroQol-5D (range 0–1): MD 0, 95% CI −0.07 to 0.07 | LOWa,b | May be little to no difference |
Overdiagnosis | ||||||
Offer-to-screen in selected populationg | Females 70–85 y (1 RCT; 6,233) [6] 14.4 × (100 − 17.9) /100 = 11.8% overdiagnosed | |||||
Females 65–90 y (1 RCT; 5575) [4] 25.4 × (100 − 23.9) / 100 = 19.3% overdiagnosed (selected higher-risk population) | ||||||
Among those considered at high risk | Females 70–85 y (1 RCT; 3064) [6] 29.3 × (100 − 17.9) / 100 = 24.1% overdiagnosed |